Jessica Vega spent years trying to quit drinking before a GLP-1 medication did what other treatments could not: it made her alcohol cravings disappear. Martha Stewart is facing pointed criticism for promoting a GLP-1 drug she says she does not take herself, and Chrissy Metz is pushing back against critics of her own weight loss. For the roughly 40 million Americans now on these medications, questions about who profits from them and who might lose coverage for them are no longer abstract.

Vega had struggled with alcohol addiction for years, trying various treatments that did not stop her cravings. She says her drinking urges disappeared after she started a GLP-1 medication, a shift that came after everything else had failed. Her experience adds to a growing body of anecdotal reports linking these drugs to reduced interest in alcohol, not just food. For someone who had tried other paths without success, this outcome came as an unexpected relief. It also raises questions about how many other people might be experiencing something similar without recognizing why.

While Vega credits her medication with changing her relationship to alcohol, Martha Stewart is facing a different kind of scrutiny over her own relationship to a GLP-1 drug. Stewart has been advertising a GLP-1 medication publicly while stating that she does not personally take it. Critics have questioned whether that arrangement is honest, given that her endorsement could shape how consumers think about the drug's use and effectiveness. The core question is straightforward: can someone credibly promote a treatment they admit they don't use themselves? The controversy is a reminder that celebrity endorsements carry real weight for a drug category already crowded with public figures weighing in.

Chrissy Metz is dealing with a related but different kind of public reaction. She has faced criticism over her own GLP-1 weight loss, with some questioning her choice to use the medication at all. Metz has pushed back directly, defending her decision as a personal one made for her own health. Her response echoes a pattern seen with other public figures who have chosen to speak openly about their GLP-1 use rather than stay silent under criticism. The willingness to defend that choice publicly stands in contrast to Stewart's more complicated position of endorsing a drug she says she avoids.

There is a more practical concern behind these public debates: insurance coverage. Losing access to GLP-1 coverage through a health plan can add hundreds of dollars to a patient's monthly costs. That gap between plans that cover the medications and those that don't is becoming a bigger factor in whether patients can continue treatment at all. For patients who have found real benefit, whether for weight loss or diabetes management, that gap can mean the difference between staying on a medication and dropping it. The stakes are higher for someone like Vega, whose benefit went beyond the reasons insurers typically recognize when they decide what to cover.

All of this touches a much larger group than the individuals named above. About 40 million Americans currently use GLP-1 medications, a number that reflects how mainstream these drugs have become. Despite that scale, common misconceptions persist about what the medications do and who takes them, misconceptions that shape everything from insurance policy decisions to public reactions toward people like Metz. Vega's experience with alcohol cravings is itself a sign of how incomplete the public understanding of these drugs still is. As more people use GLP-1 medications for a widening range of reasons, the gap between what patients experience and what the public assumes is likely to keep drawing attention.

For readers considering a GLP-1 medication or already taking one, the takeaway is to pay attention to your own experience rather than relying on assumptions from headlines or celebrity endorsements. If you notice unexpected changes, such as reduced interest in alcohol, it may be worth discussing with your doctor rather than dismissing it as unrelated. It is also worth checking your insurance plan's coverage terms now, before any changes take effect, so you are not caught off guard by a sudden increase in cost. Staying informed about both the personal and financial sides of these medications will serve you better than following any single narrative about them.

Key details

• Jessica Vega says a GLP-1 helped her stop drinking after years of addiction.

• Martha Stewart faces criticism for advertising a GLP-1 drug she says she doesn't use.

• Chrissy Metz has defended her GLP-1 weight loss experience against public criticism.

• Losing GLP-1 coverage could cost patients hundreds of dollars more each month.

• About 40 million Americans currently use GLP-1 medications despite common misconceptions.

Originally published on GLP-1 Nation.

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

Haleon, the maker of Advil, has started placing anti-nausea and digestion products next to GLP-1 drugs on store shelves, betting that people managing side effects will look for relief in the same aisle. That kind of retail strategy points to how far these medications have settled into daily life for millions of people. Roughly 40 million Americans now take drugs like Ozempic and Zepbound, and their experience with these medications touches everything from insurance coverage gaps to the research partnerships shaping what comes next.

That aisle placement is a deliberate business move. Haleon, the company behind Advil, is capitalizing on the GLP-1 boom by putting anti-nausea and digestion products where people taking these drugs will see them. Nausea is one of the most common complaints among patients on GLP-1 medications, so the company is betting that proximity turns into purchases. This is a small commercial decision, but it says something about how mainstream these drugs have become. When a company builds shelf strategy around a medication's side effects, that medication has moved from niche treatment to a routine part of many households' shopping lists.

That routine use runs into a less convenient reality for many patients: insurance coverage for GLP-1 drugs varies widely from one health plan to another. The gap between a plan that covers these medications and one that does not can add up to hundreds of dollars a month out of pocket. For patients managing diabetes or obesity, that gap can determine whether a treatment plan is sustainable over time. Anyone on one of these drugs, or considering starting one, may want to check the specifics of their coverage rather than assuming the advertised price is the price they will actually pay.

The stakes of that coverage question are large because roughly 40 million Americans are now taking GLP-1 medications such as Ozempic, Wegovy, Zepbound, and Mounjaro. That number reflects how quickly these drugs have spread beyond their original use for diabetes and into broader weight management. With so many people involved, misunderstandings about what these drugs do and do not do are common. Patients and their doctors are still working out best practices for a medication category that grew this fast.

Novo Nordisk, which makes Ozempic, is now looking to speed up that process from the research side. The company announced a partnership with Anthropic aimed at accelerating AI-assisted drug discovery, part of what Novo describes as its goal of becoming the world's most AI-driven healthcare company. The idea is that faster research could lead to new GLP-1 formulations or related treatments reaching patients sooner. It is a reminder that the drugs on shelves today are only one stage in a research effort that is still moving.

For patients trying to sort through all of this now, a recent episode of Aging Untold offers a useful starting point. The episode walks through what GLP-1 shots can and cannot do, along with the safety questions worth asking before starting one. Hosts Dr. Rhea Rogers, Sam Cradduck, and Katherine Ambrose also share their own experiences with weight loss on the show. For anyone newer to these medications, that kind of grounded explanation may be more useful than a shelf display or a corporate announcement.

If you are currently taking a GLP-1 drug, two practical steps are worth taking soon. First, check your insurance plan's specific coverage terms rather than assuming the advertised price applies to you. Second, if you are managing side effects, ask your doctor or pharmacist whether an anti-nausea product makes sense for your situation, rather than picking one off a shelf display. These decisions are more likely to shape your daily experience than either a corporate partnership or a stock placement.

Key details

• Haleon now stocks anti-nausea items near GLP-1 drugs to reach side-effect sufferers.

• Coverage gaps for GLP-1 drugs can cost patients hundreds of dollars each month.

• About 40 million Americans use GLP-1 drugs like Ozempic, Wegovy, Zepbound and Mounjaro.

• Novo Nordisk is partnering with Anthropic to speed AI drug discovery research.

• An Aging Untold episode covers what GLP-1 shots can do and safety questions to ask.

Originally published on GLP-1 Nation.

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

Berenberg upgraded Eli Lilly to buy from hold today, pointing to GLP-1 demand that shows no sign of slowing. The call lands alongside new data showing U.S. obesity rates falling to 36.4 percent, restaurant owners at the Jersey Shore adjusting their menus, and a Baton Rouge specialist reminding patients that these drugs do not work for everyone. Together they sketch a market still expanding but growing more uneven in who benefits and how businesses respond.

Investors watching Eli Lilly today got a clear signal about where analysts expect the stock to go next. Berenberg raised its rating on the company, maker of Mounjaro, to buy from hold, and the firm's reasoning centered on one point: demand for GLP-1 drugs keeps climbing, not slowing down. That view suggests Wall Street still sees plenty of room for the GLP-1 market to expand, even after a stretch of strong growth for Lilly's stock. For shareholders and for anyone tracking the broader pharmaceutical sector, the upgrade is a vote of confidence that the appetite for these drugs has not peaked.

That growing appetite is visible in new population data as well. A recent poll found U.S. obesity rates have dropped to 36.4 percent as GLP-1 use has risen, with Americans' use of these injectables for weight loss nearly quadrupling since 2024. About 11 percent of adults now take a GLP-1 medication for weight loss, and the decline in obesity rates tracked across most age groups. One exception stood out: adults 65 and older reported less benefit from the drugs than younger groups did, a gap researchers have not fully explained.

That question of who benefits, and how visibly, played out in a very different setting this week when Selena Gomez arrived at the 2026 Emmys in a glittering gold gown. Her appearance drew immediate attention, and along with it, speculation that Ozempic explained her look. Gomez has not commented on the claims, and there is no confirmation that she uses a GLP-1 medication. The episode is a reminder that any visible weight change now invites this kind of speculation, fair or not, for public figures.

That same shift is reshaping decisions of a more practical kind for restaurant owners at the Jersey Shore. Chefs there say a growing number of diners are taking GLP-1 drugs, and the change is affecting their businesses both financially and strategically. Some are rethinking portion sizes and menu offerings to match diners' smaller appetites, while others describe the shift as personal, touching their own families as well as their customer base. The restaurant industry is one of the more direct, everyday indicators of how widespread GLP-1 use has become.

That widespread use, though, does not mean the drugs work the same way for everyone. A weight-loss specialist in Baton Rouge is cautioning patients that GLP-1 medications may not deliver results for every person trying to lose weight, even as a record number of Americans take them. The specialist's warning echoes the age-related gap seen in the national obesity data, suggesting that individual response varies more than the drugs' broad popularity might imply. For patients considering these medications, that variability is worth discussing directly with a doctor rather than assuming the drugs will work as advertised.

Taken together, today's developments point to a market that keeps growing even as its effects grow less even. If you are considering a GLP-1 medication, or already taking one, it may help to look past the headlines about stocks and celebrities and focus on two questions: how well is the drug working for someone your age and health profile, and what tradeoffs are you willing to accept if the results turn out to be modest. Those questions matter more than any single earnings call or red carpet appearance.

Key details

• Berenberg upgraded Eli Lilly stock to buy from hold, citing continued GLP-1 demand growth.

• U.S. obesity rates fell to 36.4% as GLP-1 use rose, but adults 65+ saw less benefit.

• Selena Gomez faced Ozempic speculation after her glittering gold gown at the 2026 Emmys.

• Jersey Shore chefs say GLP-1 use among diners is reshaping their business plans.

• A Baton Rouge weight-loss specialist warns GLP-1 drugs do not work for everyone.

Originally published on GLP-1 Nation.

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

Arbor, a telehealth platform for compounded GLP-1 medications, announced today that it will lock prices for life and back new patients with a 12-month money-back guarantee. The move lands the same week Kentucky Medicaid rules are shown to be blocking a federal program that could have cut GLP-1 costs for residents there, and a reminder from a weight-loss expert that stopping these drugs can undo the progress they helped create. One reader's story of losing eight stone without ever touching Mounjaro or Wegovy adds another angle entirely.

The lifetime price lock is the central feature of Arbor's offer. Arbor is telling patients that whatever rate they lock in when they start treatment stays fixed for as long as they remain on the plan, through its telehealth platform for compounded GLP-1 medications. The 12-month money-back guarantee adds a second layer of protection, giving new patients a full year to decide whether the medication is working for them before they are locked into a plan they regret. For patients comparing options, that combination of a guaranteed price and a refund window may be worth weighing against other telehealth providers.

That price lock starts at $99 per month for compounded semaglutide and tirzepatide plans, according to Arbor's program details. Patients connect with licensed providers online who review their eligibility before prescribing either medication, a process similar to other telehealth weight-loss platforms already on the market. The final monthly cost will still depend on the specific plan and dose a provider recommends, so the $99 starting rate should be treated as a floor rather than a guaranteed price for every patient. Anyone considering the offer should confirm exactly what is included in that starting rate before committing to a full year of treatment.

Cost is also the sticking point in Kentucky, where a federal Medicare program could in theory bring down what some patients pay for GLP-1 drugs. The problem is that Kentucky's Medicaid rules were not written with this kind of coverage in mind, and those older rules are currently standing in the way of residents who would otherwise benefit. The gap points to a familiar pattern, where federal programs move to expand access but state-level rules take time to catch up. Until Kentucky updates its Medicaid framework, patients there will need to look at private options, including telehealth platforms, if they want a lower monthly cost.

Price is one part of the GLP-1 decision, and what happens after treatment is another. A patient recently asked an expert a direct question: if they stop taking the medication, will they lose the progress they made? The expert's answer was straightforward. Stopping a GLP-1 medication can lead to regaining the weight that was lost while on it, because the drug's effect on appetite and metabolism does not necessarily carry over once treatment ends. That answer is worth weighing alongside any pricing offer, since a lower monthly cost still means committing to treatment for the long term if the goal is to keep the weight off.

Not every weight-loss result comes from a GLP-1 medication, though. One person shared that they lost eight stone and reached what they describe as the best shape of their life without ever using Mounjaro or Wegovy. Their story stands as a reminder that these medications are one path among several, not the only route to significant weight loss. For readers weighing whether a GLP-1 plan is worth the cost, it may help to remember that non-drug approaches remain part of the picture too.

For readers shopping for compounded GLP-1 plans, the practical takeaway is to read the terms behind any lifetime price lock or money-back guarantee before signing up, and to ask what the monthly rate will actually cover as doses change. It also helps to think past the first year of treatment, considering what happens if you stop and whether you have a plan for maintaining results either way. If you're in Kentucky and hoping a federal program will lower your GLP-1 costs, it is worth contacting your Medicaid office directly to ask when state rules might change. Whatever path you choose, the medication is a tool, not the only route to reaching your goal.

Key details

• Arbor locks GLP-1 prices for life and offers a 12-month money-back guarantee.

• Compounded semaglutide and tirzepatide plans through Arbor start at $99 per month.

• A federal Medicare program could cut GLP-1 costs, but Kentucky's Medicaid rules block it.

• Stopping a GLP-1 medication may lead to regaining lost weight, according to an expert.

• One person lost eight stone and reached their best shape without using Mounjaro or Wegovy.

Originally published on GLP-1 Nation.

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

Researchers gave semaglutide, the drug in Ozempic and Wegovy, to elderly female mice, and the treated mice lived about 12 percent longer than the ones that went untreated. That is close to 100 extra days of a mouse life. They also did better on tests of muscle function, thinking and spatial memory.

The honest version of that finding is narrower than the headline it is going to get. This was a study in mice, and a mouse lifespan study does not show that a person taking semaglutide will live longer or age more slowly. The researchers are now looking at whether the drug is acting on inflammation and other pathways tied to age related decline, which is the part that would eventually matter for people. That work has not been done yet.

Muscle came up again this week from a different direction. A review of the GLP-1 trials, including Novo Nordisk's STEP 1 trial of semaglutide, found lean body mass accounted for 25 to 39 percent of the total weight people lost. That is not unique to these drugs, it happens with most weight loss, but it is worth watching in older adults, in menopausal women and in anyone already low on muscle, because losing too much of it affects balance, strength and how well someone moves. Resistance exercise and enough protein are still the two things that protect it.

A study in Clinical Nutrition described 15 reported cases of Wernicke encephalopathy in people taking GLP-1s. It is a rare brain condition caused by a severe deficiency of vitamin B1. Most of the people in those reports had gastrointestinal or nutrition problems first: vomiting, loss of appetite, malnutrition. The researchers say plainly that 15 case reports cannot show the medication caused it, and they have asked for more work before anyone draws a conclusion. What it does underline is that eating very little for months on end has consequences of its own.

And the number of bariatric surgeries in the United States fell below 200,000 in 2024, the first time since 2020 and a drop of more than 20 percent in a year. The Baton Rouge Advocate followed one woman through the other direction: GLP-1 injections made her sick, so she had a sleeve gastrectomy instead, and she has lost 115 pounds, 87 of them after the surgery.

Four studies, four different questions, and none of them settles anything on its own. The lifespan result is early and it is in mice. The muscle and vitamin findings are the ordinary maintenance side of being on one of these drugs, the part that gets less attention than the scale does.

Key details

• Semaglutide extended the lifespan of elderly female mice by about 12 percent, close to 100 extra days, and the treated mice did better on muscle, cognitive and spatial memory tests.

• The study does not show that people taking semaglutide will live longer or age more slowly.

• Lean body mass accounted for 25 to 39 percent of total weight lost in GLP-1 trials, including STEP 1. Resistance exercise and enough protein help protect it.

• A Clinical Nutrition study described 15 reported cases of Wernicke encephalopathy, a rare vitamin B1 deficiency condition, in people taking GLP-1s. Most had vomiting or appetite loss first, and the report does not prove the drugs caused it.

• Bariatric surgery in the United States dropped below 200,000 procedures in 2024, down more than 20 percent from the year before.

Sources

• Vanguard: Weight-loss drug may also slow ageing, study says

• Medscape: Muscle Loss on GLP-1s: Data and Debate

• Fox News: Ozempic and Wegovy may cause rare brain disorder, new study warns

• Baton Rouge Advocate: In GLP-1 era, this Baton Rouge couple chose surgery instead

Originally published on GLP-1 Nation.

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

Restaurants have spent two years watching the same thing happen at their tables. Plates come back with food still on them. Parties order fewer courses. The check comes out smaller. Enough American kitchens have now noticed the pattern that they are doing something about it, and what they are doing is making the portions smaller on purpose.

The number behind it is the reason. About one in eight American adults currently takes a GLP-1 medicine such as Wegovy or Mounjaro, and 11 percent of adults are taking one specifically for weight loss, up from 3 percent in 2024. That is a large enough share of a dining room that a restaurant cannot plan a menu around the old assumptions any more.

What changes at the table is not just how much. Most people taking a GLP-1 report ordering differently once they start: smaller portions, more protein, more vegetables. A kitchen that only shrinks the plate and changes nothing else is answering half the question, which is why some of the menu changes showing up now are new smaller dishes rather than the same dish with less on it.

The part that surprises people is that this is not a story about GLP-1 users staying home. Eighty-seven percent of them say they still enjoy going out to eat and count restaurants as part of their life. They are still at the table. They are ordering a different meal than they used to, and the restaurants that have worked that out are the ones adjusting the menu instead of waiting to see what happens.

It is worth saying what this does not settle. A smaller portion at a lower price is good news if it arrives as a real option, and less good if it arrives as the same price for less food. Which of those it turns out to be is going to vary restaurant by restaurant, and it is early enough that nobody can tell you yet how that lands across the country.

If you take a GLP-1 and you have been quietly ordering an appetizer as your main course, you are not doing anything unusual. You are part of a group big enough that kitchens are now building menus around it.

Key details

• One in eight American adults currently takes a GLP-1 drug such as Wegovy or Mounjaro.

• Eleven percent of US adults take a GLP-1 for weight loss, up from 3 percent in 2024.

• Most GLP-1 users have changed how they order at restaurants, generally choosing smaller portions, more protein and more vegetables.

• Eighty-seven percent of GLP-1 users say they still enjoy eating out and consider restaurants part of their lifestyle.

• Some American restaurants are responding by reducing portion sizes and adding smaller dishes to the menu.

Sources

• Irish Dentist: The GLP-1 effect comes to the dinner table: Why American restaurants are reducing portions

Originally published on GLP-1 Nation.

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

China approved Novo Nordisk's Wegovy today as the first GLP-1 drug cleared to treat MASH, a serious liver disease, opening a new market even as the company's stock slid at home. Morgan Stanley downgraded Novo Nordisk over the coming patent cliff facing semaglutide, and investors responded fast. Jim Cramer told viewers he favors Johnson & Johnson over Eli Lilly and Pfizer among healthcare stocks, while Amgen laid out its own growth case built on newer drugs. It was a day that touched the science and the money behind these medicines.

On CNBC, Jim Cramer said he'd rather own Johnson & Johnson than Eli Lilly or Pfizer right now, citing the diversification that comes from J&J's broader portfolio outside weight loss drugs. For investors who have leaned heavily into GLP-1 names, that is a reminder that the obesity drug boom has not lifted every healthcare stock the same way. Lilly and Pfizer still carry real exposure to this market, but Cramer's preference suggests some fund managers are looking for steadier bets as the field matures. His comments do not change the underlying science, but they do shape how money moves toward these companies in the near term.

Novo Nordisk also released data today showing that semaglutide lowered BMI in 40.4% of obese children who took it, a result the company is presenting as evidence its drug can help younger patients, not just adults. Pediatric obesity treatment has moved more slowly than the adult market, in part because regulators require longer safety follow-up for children, so this figure gives Novo something concrete to bring to future approval discussions. Parents and physicians weighing options for children with obesity now have another data point to consider, though the company has not yet said when or whether it will seek a specific pediatric indication tied to this number. The result also underscores how much of Novo's current strategy depends on expanding semaglutide's approved uses beyond the adult weight loss market that made it famous.

That same strategy of expanding semaglutide's approved uses reached China today, where regulators cleared Wegovy as the first GLP-1 drug approved there for MASH, a liver disease linked to obesity and metabolic dysfunction. The approval opens a substantial new market for Novo Nordisk, since MASH affects a growing share of patients in China as obesity rates have risen there. It also reinforces semaglutide's reputation as a drug with effects that reach beyond weight loss alone, touching organs like the liver in ways that matter to patients with more advanced metabolic disease. For Novo, the timing matters too, since this approval offers a new growth avenue right as the company faces pressure elsewhere in its business.

While Novo Nordisk works to expand semaglutide's footprint, Amgen used today's disclosures to make its own growth case, pointing to drivers it says could add 26% growth to its business. The company highlighted IMDELLTRA, a cancer treatment gaining momentum, alongside MariTide, its own obesity drug candidate still working through development. Amgen's message was straightforward: unlike some peers facing patent pressure, it has multiple products it expects to carry growth over the next several years. For a company competing in the same obesity drug market as Novo and Lilly, that message also serves as reassurance to investors that MariTide is not its only path forward.

That contrast, other companies naming several growth paths while Novo works to build support for MASH and pediatric approvals, ties directly to why Morgan Stanley downgraded Novo Nordisk today. The firm's analysts flagged the coming patent cliff for semaglutide as the year approaches when competitors gain the ability to launch cheaper generic versions of the drug. Novo Nordisk shares dropped on the news, reflecting investor concern that the company's core revenue driver faces a firm expiration date, even as it works to expand into new markets like China's MASH treatment approvals. The downgrade does not erase Novo's recent wins, but it does put a clock on how much time the company has to convert this global expansion into lasting revenue.

Taken together, today's developments point to a simple reality: Novo Nordisk is racing to open new markets and prove new uses for semaglutide at the same time analysts are counting down to when its exclusivity ends. If you hold Novo Nordisk stock, it may be worth watching how quickly the MASH approval in China and the pediatric BMI data translate into new revenue lines, since that is likely what will offset the patent cliff Morgan Stanley flagged. If you are weighing healthcare stocks more broadly, Cramer's preference for J&J and Amgen's own growth pitch are worth factoring in alongside Lilly and Pfizer, rather than assuming every company in this market carries the same risk profile. Talk to a financial advisor before making decisions based on any single analyst call or company disclosure.

Key details

• Jim Cramer favors J&J over Eli Lilly and Pfizer, a signal worth noting if you track…

• Novo Nordisk reports that semaglutide helped 40.4% of obese children lower their BMI in…

• China has approved Wegovy as the first GLP-1 drug for treating MASH, a liver disease,…

• Amgen points to 26% growth drivers, along with momentum from IMDELLTRA and potential…

• Morgan Stanley's downgrade over the coming semaglutide patent cliff sent Novo Nordisk…

Originally published on GLP-1 Nation.

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

Jim Cramer highlighted Eli Lilly today, pointing to its GLP-1 growth as the reason he now considers the stock a core holding. That comment landed alongside a more cautionary signal from CMS, which is hinting at audits of the GLP-1 Bridge program that helps patients access these drugs. A Novo Nordisk data breach tied to stolen GitHub tokens rounds out a day that mixed market enthusiasm with real operational risk.

Cramer's comments today framed Eli Lilly's tirzepatide-driven growth, from Zepbound and Mounjaro, as durable enough to make LLY a stock investors should hold regardless of short-term swings in the broader market. He described the company as a dependable holding investors can build a portfolio around, arguing that the underlying demand for GLP-1 drugs gives Lilly growth other companies in the sector cannot easily match. His confidence rests on the assumption that demand keeps climbing and that Lilly can keep supplying it. That assumption is about to be tested by a different kind of scrutiny than Wall Street usually applies.

CMS is signaling it may open audits of the GLP-1 Bridge program, the mechanism that has helped patients access these medications when insurance coverage falls short or lapses. An audit would look at how the program verifies eligibility and dispenses drugs, and any findings could tighten the rules that currently make access easier for some patients. For a company counting on continued patient uptake, added requirements in an access program matter because they can slow the demand growth Cramer is betting on. The signal is early, but it is worth watching how CMS frames the review in the coming weeks.

Novo Nordisk, Lilly's chief rival in the GLP-1 market, disclosed a data breach today traced to stolen GitHub access tokens. The breach highlights a risk that has nothing to do with drug demand or regulatory audits: the technical infrastructure that supports these companies as they scale. Novo has not detailed the scope of data exposed, but the incident is a reminder that as GLP-1 manufacturers grow into complex international operations, the code and systems behind them become bigger targets. For investors weighing Cramer's enthusiasm about Lilly against the risks facing Novo, this breach adds a concrete data point about how exposed these companies are becoming as their operations expand.

Beyond any single company, a broader debate is playing out among analysts: whether weight-loss drugs or artificial intelligence will reshape the economy first. Those focused on GLP-1 drugs point to potential shifts in healthcare costs and consumer spending as more people use these drugs long-term. Those focused on AI point instead to labor markets, arguing that automation could change which jobs exist faster than any drug changes health outcomes. Cramer's comments on Lilly and the operational challenges facing Novo both speak to one side of that debate, since both companies are central to the case for GLP-1 drugs as an economic force.

While analysts debate the macro effects of GLP-1 drugs, new research published today looked at a much more personal question for patients: does Ozempic use have any connection to hair loss? The research does not settle the question definitively, but it adds to a small and growing body of work examining side effects that patients have reported anecdotally rather than confirmed in early clinical trials. Anyone concerned about hair loss while taking Ozempic should raise it with their prescriber, since individual factors vary and a single study is not a substitute for that conversation. The research is a reminder that side-effect profiles for these drugs are still being filled in even as usage grows.

Taken together, today's stories give readers two different views of the same trend: one focused on markets and access, the other on the everyday experience of taking these drugs. Investors weighing Cramer's confidence in Lilly should also track how CMS's review of the GLP-1 Bridge program unfolds, since it could affect patient access at scale. Patients already using Ozempic or similar drugs should keep an open conversation going with their prescriber about any side effects they notice, including hair loss. GLP-1 drugs are moving from a niche treatment into a mainstream part of the economy, and that shift brings both opportunity and scrutiny in equal measure.

Key details

• Jim Cramer flagged Eli Lilly's GLP-1 growth as reason to view LLY as a core stock to own.

• CMS is signaling it may audit the GLP-1 Bridge program used for patient access.

• Novo Nordisk suffered a data breach traced to stolen GitHub access tokens.

• Analysts are debating whether weight-loss drugs or AI will reshape the economy first.

• New research explores whether Ozempic use has any connection to hair loss.

Sources

• Insider Monkey: Eli Lilly (LLY) GLP-1 Growth Made It a Core Running Back Stock for Jim Cramer

• NCPA: CMS hints at GLP-1 Bridge audits

• BankInfoSecurity: Novo Nordisk Data Breach Tied to Stolen GitHub Access Tokens

• NZ Herald: Weight-loss drugs v AI: Which one will reshape the economy first

• Vice: Does Ozempic Really Make You Lose Your Hair? Here's What New Research Suggests

Originally published on GLP-1 Nation.

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

Analysts have put a $92 price target on Viking Therapeutics, but reaching it depends on trial data and launch timing lining up in the months ahead. Eli Lilly's stock crossed a trillion dollars in market value today, and a UK study found Ozempic and Wegovy users had far fewer asthma attacks. A Connecticut drugmaker is betting on an inhaled alternative, while employers look for sustainable ways to cover this class of drugs. Each story asks what has to happen next before this momentum becomes real.

That $92 price target on Viking Therapeutics carries real conditions attached. Analysts base it on a series of milestones lining up correctly: clean trial results, a launch that lands on schedule, and a market willing to keep backing a challenger to Lilly and Novo Nordisk. If any of those pieces slips, the valuation case gets harder to defend. For investors watching Viking as a possible alternative in this market, the stock's upside depends less on what the company has already shown and more on what it still has to prove.

Eli Lilly's climb to a trillion dollars in market value puts a sharper point on that same question of timing. The company got there on the strength of its GLP-1 franchise, and that scale is exactly why some investors are asking whether the easy gains have already happened. A trillion-dollar valuation does not mean the stock is finished moving, but it does mean new buyers are paying for growth that has, in large part, already arrived. Anyone considering a position now would do well to weigh that against companies like Viking, where the growth, if it comes, is still ahead of the stock rather than behind it.

Employers face their own version of a timing problem, since GLP-1 coverage costs have made this benefit hard to sustain year over year. A new whitepaper argues that captive insurance, where a company or group of companies self-funds and shares risk rather than buying a fully insured plan, offers one way to keep offering these drugs without costs spiraling. The appeal is that it gives employers more control over how claims are managed and priced over time. For HR and benefits teams under pressure to keep GLP-1 coverage in place, this is a structural option worth discussing with a broker or actuary, rather than a guarantee that costs will fall.

On the patient side, a UK records study adds a new data point to the drugs' effects beyond weight and blood sugar. Researchers found that people taking Ozempic or Wegovy had nearly 40 percent fewer asthma attacks compared with those not on the drugs. The study does not establish why, but it fits a growing pattern of GLP-1 drugs showing benefits in conditions connected to inflammation and metabolic health. For patients managing both diabetes or obesity and asthma, this is worth raising with a doctor, though it is not a reason to change asthma treatment on its own.

That same interest in what these drugs can do beyond weight loss extends to how they are delivered. A Connecticut drugmaker has partnered on developing an inhaled weight-loss treatment, aiming to give patients an alternative to weekly injections. If it succeeds, an inhaled option could appeal to people who avoid GLP-1 treatment because of needle aversion or the logistics of injections. Inhaled delivery for a drug class built on injections is a real technical challenge, so this is a development worth watching rather than something patients should expect soon.

Across these stories, the common thread is patience. Viking's valuation, Lilly's next move, employer coverage strategies, and the search for new ways to deliver these drugs all rest on developments that have not fully played out yet. Readers weighing a Viking or Lilly position should look at the specific trial and launch dates that these price targets and market caps assume, rather than the headline numbers themselves. And if you are an employer or benefits manager, it is worth asking your broker directly whether a captive insurance structure could fit your group before costs force a harder decision.

Key details

• Viking's path to a $92 stock price depends on trial results and launch timing.

• Eli Lilly's stock has topped a trillion dollars, raising questions about buying now.

• A new whitepaper says captive insurance could give employers sustainable GLP-1 coverage.

• A UK study found Ozempic and Wegovy users had nearly 40 percent fewer asthma attacks.

• A Connecticut drugmaker has partnered to develop an inhaled weight-loss treatment.

Sources

• AOL: Analysts Have a $92 Target on Viking Therapeutics. Here Is What Has to Go Right to Get There.

• Yahoo Finance: Eli Lilly Stock Has Become a Trillion-Dollar Giant. Is It Too Late to Buy?

• Captive Insurance Times: MAXIS GBN whitepaper flags captives as a route to sustainable GLP-1 cover

• IBTimes: Ozempic and Wegovy Tied to Nearly 40% Fewer Asthma Attacks, UK Records Study Finds

• Hartford Business Journal: CT drugmaker partners on development of inhaled weight-loss treatment

Originally published on GLP-1 Nation.

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

Analysts have put a $92 price target on Viking Therapeutics, but reaching it depends on trial data and launch timing lining up in the months ahead. Eli Lilly's stock crossed a trillion dollars in market value today, and a UK study found Ozempic and Wegovy users had far fewer asthma attacks. A Connecticut drugmaker is betting on an inhaled alternative, while employers look for sustainable ways to cover this class of drugs. Each story asks what has to happen next before this momentum becomes real.

That $92 price target on Viking Therapeutics carries real conditions attached. Analysts base it on a series of milestones lining up correctly: clean trial results, a launch that lands on schedule, and a market willing to keep backing a challenger to Lilly and Novo Nordisk. If any of those pieces slips, the valuation case gets harder to defend. For investors watching Viking as a possible alternative in this market, the stock's upside depends less on what the company has already shown and more on what it still has to prove.

Eli Lilly's climb to a trillion dollars in market value puts a sharper point on that same question of timing. The company got there on the strength of its GLP-1 franchise, and that scale is exactly why some investors are asking whether the easy gains have already happened. A trillion-dollar valuation does not mean the stock is finished moving, but it does mean new buyers are paying for growth that has, in large part, already arrived. Anyone considering a position now would do well to weigh that against companies like Viking, where the growth, if it comes, is still ahead of the stock rather than behind it.

Employers face their own version of a timing problem, since GLP-1 coverage costs have made this benefit hard to sustain year over year. A new whitepaper argues that captive insurance, where a company or group of companies self-funds and shares risk rather than buying a fully insured plan, offers one way to keep offering these drugs without costs spiraling. The appeal is that it gives employers more control over how claims are managed and priced over time. For HR and benefits teams under pressure to keep GLP-1 coverage in place, this is a structural option worth discussing with a broker or actuary, rather than a guarantee that costs will fall.

On the patient side, a UK records study adds a new data point to the drugs' effects beyond weight and blood sugar. Researchers found that people taking Ozempic or Wegovy had nearly 40 percent fewer asthma attacks compared with those not on the drugs. The study does not establish why, but it fits a growing pattern of GLP-1 drugs showing benefits in conditions connected to inflammation and metabolic health. For patients managing both diabetes or obesity and asthma, this is worth raising with a doctor, though it is not a reason to change asthma treatment on its own.

That same interest in what these drugs can do beyond weight loss extends to how they are delivered. A Connecticut drugmaker has partnered on developing an inhaled weight-loss treatment, aiming to give patients an alternative to weekly injections. If it succeeds, an inhaled option could appeal to people who avoid GLP-1 treatment because of needle aversion or the logistics of injections. Inhaled delivery for a drug class built on injections is a real technical challenge, so this is a development worth watching rather than something patients should expect soon.

Across these stories, the common thread is patience. Viking's valuation, Lilly's next move, employer coverage strategies, and the search for new ways to deliver these drugs all rest on developments that have not fully played out yet. Readers weighing a Viking or Lilly position should look at the specific trial and launch dates that these price targets and market caps assume, rather than the headline numbers themselves. And if you are an employer or benefits manager, it is worth asking your broker directly whether a captive insurance structure could fit your group before costs force a harder decision.

Key details

• Viking's path to a $92 stock price depends on trial results and launch timing.

• Eli Lilly's stock has topped a trillion dollars, raising questions about buying now.

• A new whitepaper says captive insurance could give employers sustainable GLP-1 coverage.

• A UK study found Ozempic and Wegovy users had nearly 40 percent fewer asthma attacks.

• A Connecticut drugmaker has partnered to develop an inhaled weight-loss treatment.

Originally published on GLP-1 Nation.

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

Novo Nordisk held its first India Day in Bengaluru today, bringing company leadership together with local health and research partners to mark what it calls a long-term commitment to India's health and science future. The gathering reflects how GLP-1 makers are now planning years, not quarters, ahead. That same forward-looking mood carries through today's other developments, from stock forecasts to fresh research on how these drugs might help beyond diabetes and weight loss.

The Bengaluru event brought Novo's leadership together with researchers and public health partners from across India's science community. The company framed the day around research partnerships and sustainability commitments rather than any single product launch, the kind of institutional relationship that outlasts a single drug cycle. That framing matters for a market where Novo's GLP-1 medicines are still expanding access, since the company is signaling a lasting presence rather than a short-term distribution push. For a country with growing rates of diabetes and obesity, this kind of long-term positioning can affect how quickly new treatments and research reach patients.

Turning from strategy to stock price, a new financial forecast looks at what a $5,000 investment in Eli Lilly today might be worth by 2031, using the company's growth in GLP-1 medicines as the basis for its projection. Lilly's rise has been driven largely by demand for its diabetes and weight-loss drugs, and forecasts like this one are becoming more common as investors try to gauge how much room is left in the company's valuation. I would suggest reading these projections as one input among several, since they rest on assumptions about future sales that may or may not hold. Still, the fact that this kind of long-range forecast is being published says something about how central Lilly has become to conversations about the GLP-1 market's future.

That same growth story extends beyond diabetes and weight loss, as a new study points to a GLP-1 ingredient's potential to reduce asthma attacks and COPD flare-ups. Researchers found a link between the ingredient and fewer respiratory flare-ups in patients, adding to a growing body of evidence that GLP-1 drugs may have effects beyond their original indications. This kind of finding is still early, and a link identified in a study is not the same as a proven treatment effect, so I would suggest patients with asthma or COPD talk to their doctor before drawing conclusions about their own care. If the effect holds up in further research, it could change how these medications are used in respiratory disease.

The research pipeline is also producing new companies, not just new findings. Kura is spinning its diabetes research program into an independent biotech startup, with backing from Eli Lilly. This kind of arrangement lets a larger pharmaceutical company support early-stage science without absorbing it directly into its own operations, while the smaller team retains more control over its own direction. For Lilly, the move expands its involvement in diabetes research beyond its existing drug portfolio, and it reflects a broader pattern of large GLP-1 companies investing in adjacent science rather than developing everything in-house.

Not every voice in the market is bullish on Lilly's trajectory, though. Jim Cramer has said he prefers Johnson & Johnson over both Eli Lilly and Pfizer among healthcare stocks, a preference that runs against the enthusiasm reflected in some of today's other coverage. His view is a reminder that even with strong demand for GLP-1 drugs, not every analyst treats Lilly as the automatic top pick in the sector. Readers weighing their own positions may want to look at both sides of that argument rather than following either view on its own.

Taken together, today's stories point to a company thinking about its future in India and investors thinking about Lilly's future in the market, both looking well past the current quarter. If you hold Lilly stock or are considering it, it may be worth reading both the growth forecast and Cramer's more cautious take before deciding where you stand. If you or someone you know manages asthma or COPD, keep an eye on how the respiratory research develops, since early findings like this often take years to translate into actual treatment options. For now, the clearest signal is that GLP-1 companies are building for the long term, both in new markets like India and in the smaller ventures now spinning out of their research programs.

Key details

• Novo's first India Day in Bengaluru signals lasting investment in health and science.

• One financial forecast estimates what a $5,000 stake in Eli Lilly could grow to by 2031.

• A new study suggests a GLP-1 ingredient may reduce asthma attacks and COPD flare-ups.

• Kura is turning its diabetes research into a new biotech startup backed by Lilly.

• Jim Cramer favors Johnson & Johnson over Eli Lilly and Pfizer among healthcare stocks.

Originally published on GLP-1 Nation.

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

Mounjaro's new heart benefit data is drawing attention from investors who have mostly valued Lilly on the strength of its weight loss franchise. If the drug's cardiovascular effects hold up as a distinct selling point, that gives Lilly a second story to tell beyond pounds lost, one that could open the door to a broader set of patients and prescribers who weigh heart risk heavily in their treatment decisions. Some analysts see this as the start of a new phase for the stock, where GLP-1 sales are no longer the only lever driving Lilly's valuation higher. That shift would not happen overnight, but it changes the conversation around what Mounjaro is worth to the company long term.

That broader growth story gets another boost from Lilly's acquisition spree, which has picked up pace in recent months. The company has been adding capabilities and pipeline assets through a series of deals, and some investors are trying to work out how much of that dealmaking could add to the stock price down the road. The logic is straightforward: if Lilly can pair strong existing sales with new assets bought at reasonable prices, the combination gives the stock more than one way to keep climbing. How much of that potential is already priced in remains an open question, and it is one Lilly's next earnings report may help answer.

Not every part of the GLP-1 story looks as favorable for patients, though. Medicare's new discount program for GLP-1 drugs does not cover everyone who might want in, and coverage rules mean some beneficiaries will still face costs the discount was meant to ease. That gap affects people who assumed the program would apply broadly, and it is a reminder that policy headlines do not always translate into access for every patient. Anyone relying on Medicare for these drugs would do well to check their own plan's rules rather than assume the discount applies to them.

While Lilly works through its own set of catalysts, Novo Nordisk added one of its own this week. A new trial result for Wegovy gives the company another data point to point to as it competes for share in a market Lilly is also chasing hard. For Novo, a fresh clinical win serves a similar purpose to Lilly's heart data: it gives investors and prescribers another reason to keep Wegovy in the conversation rather than ceding ground to newer competitors. The two companies are, in effect, racing to add reasons for patients and payers to choose their drug over the other's.

Novo Nordisk also has a study result touching a different population entirely. The study found that Wegovy helped 40% of young children in the trial overcome obesity, a result that speaks to a much younger age group than the adult weight loss market most GLP-1 coverage focuses on. That finding could matter for parents and pediatricians weighing treatment options for children who have not responded to other approaches, though any decision about a child's treatment should involve their own doctor rather than a headline number. It also gives Novo another avenue for Wegovy's use beyond the adult market Lilly is competing hardest for.

Taken together, today's news shows two large companies working from different angles to extend their GLP-1 franchises, one through new clinical data and one through acquisitions and pipeline expansion. For readers with a financial interest, the near-term signal to watch is how analysts and Lilly's next earnings call treat the heart data and deal spree separately, since conflating the two could overstate what either has actually proven. For readers with a personal or family interest in these drugs, the more useful step is to check your own Medicare plan's rules on the GLP-1 discount and, if a child's weight is the concern, to raise the pediatric study with their doctor directly rather than acting on the headline alone.

Key details

• Mounjaro's new heart benefit data may fuel further growth for Lilly's stock.

• Lilly's recent acquisition spree could add further momentum to its stock price.

• Not everyone qualifies for the new Medicare discount on GLP-1 drugs.

• A new trial result gives Novo Nordisk another growth catalyst for Wegovy.

• A study found Wegovy helped 40% of young children overcome obesity.

Read this on GLP-1 Nation: https://glp1nation.com/edition/43

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

The research on GLP-1s and opioid addiction is still early, but it points to a use for these medications that has nothing to do with blood sugar or body weight. Scientists want to know if the same drugs that curb appetite might also dampen the reward circuits that drive substance use. If that connection holds up under further study, it would mark a real expansion of what these medications are understood to do. For now, the work is a signal to watch rather than a treatment available to patients.

That kind of careful, incremental science stands in sharp contrast to a claim that spread widely today, describing Ozempic as a "fascist" plot to eliminate overweight people. The claim offers no evidence and reflects the kind of rhetoric that surrounds these drugs more than any finding about how they work. It shows how much suspicion still attaches to GLP-1 medications, even as researchers pursue legitimate new applications for them. Readers should weigh claims like this one against the actual research building around these drugs, including the addiction study described above.

Access to these medications is its own story, and in the UK, that access can be strict enough to sound absurd. Under current NHS rationing rules, some patients must weigh as much as a sumo wrestler before they qualify for weight loss jabs. That threshold reflects how tightly the health service is trying to control costs and prioritize the patients it considers most in need. For people who fall just under that bar but still struggle with their weight, the rule can feel arbitrary and out of reach. It is a reminder that eligibility for these drugs varies enormously depending on where a patient lives and what system they rely on.

Once a patient does get access, the next question is what these drugs do beyond the body, and new research offers a reassuring answer with one exception. The findings suggest GLP-1 drugs are largely safe from a psychiatric standpoint, without the widespread mood or mental health risks that some had worried about. But the research does flag one finding that still raises questions, and it is significant enough that scientists say it deserves more attention rather than a quick dismissal. Patients and doctors should treat this as an encouraging result with an asterisk, not a clean bill of health.

The mental health caveat fits a broader pattern with these drugs: real benefits paired with side effects that are only now getting full attention, and hair loss is a clear example. One writer described how weight loss jabs thinned her hair, turning it into what she called wispy strands, and how she went about restoring it. Her account is a practical one, focused on the steps she took rather than a warning against the drugs themselves. For readers noticing similar changes, her experience offers a concrete data point on managing a side effect that does not get discussed as often as nausea or appetite loss.

Across all of this, the same drugs are being studied for new uses, misrepresented in viral claims, rationed under strict rules, and evaluated for their psychiatric effects, and patients on the ground are still managing the day to day side effects. Readers should keep two things in mind. First, treat sensational claims about these drugs with real skepticism until better evidence arrives. Second, pay attention to the steadier research on safety and access, since that is what will actually shape whether and how a person can use these medications going forward.

Key details

• Researchers are studying whether GLP-1 medications could help treat opioid addiction.

• A viral claim called Ozempic a "fascist" plot to eliminate overweight people.

• NHS rules require some patients to weigh as much as a sumo wrestler for weight loss jabs.

• New research suggests GLP-1 drugs are largely safe for mental health, with one caveat.

• One writer shared how weight loss jabs thinned her hair, and how she restored it.

Read this on GLP-1 Nation: https://glp1nation.com/edition/41

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

Druckenmiller's Duquesne Family Office and Griffin's Citadel both increased their stakes in Eli Lilly during the most recent quarter, according to regulatory filings. Neither investor is known for chasing hype, and their moves suggest a read on Lilly's fundamentals rather than a bet on short-term stock swings. Lilly's GLP-1 drugs, Mounjaro and Zepbound, have driven much of the company's recent growth, and institutional buying at this scale tends to draw attention from retail investors who track filings for cues. That attention matters for readers who hold Lilly shares directly or through funds, since large purchases by prominent managers can influence how other investors perceive the stock's near-term direction.

Viking Therapeutics tells a different story. Its shares currently trade well below the price targets that Wall Street analysts have set, and that gap has drawn out skeptics who question whether the company's obesity drug candidate can compete with established players like Lilly and Novo Nordisk. The skeptical case centers on execution risk: Viking still needs to clear trial and approval hurdles that Lilly has already passed with its own GLP-1 products. For investors weighing whether the discount reflects a buying opportunity or a fair warning, the answer depends on how much confidence they place in Viking's pipeline reaching the market on schedule.

That contrast between an established leader and an unproven challenger sets up the next question directly: what does a stake in Lilly itself look like a few years from now? A new prediction models what a $5,000 investment in Eli Lilly today could become in five years, based on the company's current growth trajectory in its GLP-1 business. The projection leans on continued demand for Mounjaro and Zepbound and on Lilly's ability to keep expanding manufacturing capacity to meet it. Readers should treat any five-year forecast as one scenario among several, since drug pricing policy, competition, and manufacturing constraints could all shift the outcome in either direction.

Away from the stock market, a new study looked at a side effect that has come up often in patient reports: hair loss during GLP-1 treatment. Researchers found a genetic link between weight loss medicines and hair loss specifically in men, suggesting that some individuals may carry a predisposition that makes this side effect more likely for them. The finding does not mean hair loss is inevitable for men on these drugs, but it does give doctors and patients another factor to discuss when weighing the medicines' benefits against their side effects. Readers who have noticed hair thinning while on a GLP-1 drug may want to raise this study with their prescriber rather than draw conclusions on their own.

A second study published today shifts the focus to an even younger group of patients. Researchers found that more children under age 12 in the United States are being prescribed GLP-1 weight-loss drugs, a trend that has grown alongside the medicines' rising use in adults. The study does not detail the long-term effects of these drugs in such young patients, and that gap in the research is likely to shape how pediatricians and parents approach prescribing decisions going forward. Combined with the hair loss findings, it points to a broader need for more data on how GLP-1 medicines affect different groups of patients over time.

Taken together, today's developments point in two directions at once: growing confidence in Lilly's business from some of the most experienced investors in the market, and growing caution from researchers studying how these drugs affect patients, including men prone to hair loss and children as young as the ones now being prescribed them. Readers holding Lilly or Viking stock should weigh the financial case on its own terms, separate from the clinical questions still being studied. And anyone considering a GLP-1 medicine for themselves or a child should bring these new findings to a conversation with their doctor rather than treat them as a final answer.

Key details

• Stanley Druckenmiller and Ken Griffin have both been buying up shares of Eli Lilly.

• Viking Therapeutics shares trade well below Wall Street price targets, drawing skeptics.

• A new prediction shows what a $5,000 Eli Lilly investment could become in five years.

• A new study found a genetic link between weight loss medicines and hair loss in men.

• A new study finds more US children under 12 are being prescribed GLP-1 weight-loss drugs.

Read this on GLP-1 Nation: https://glp1nation.com/edition/40

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

This week's roundup pulls together voices from Novo Nordisk and Eli Lilly, the two companies making the drugs at the center of this boom, alongside Bupa and the UK Health Security Agency, which represent the insurance and public health side of the story. That combination matters because it shows how far this conversation has moved outside the drug companies themselves. Insurers are now weighing how to cover these treatments, and public health bodies are tracking their effects at a population level, not just in clinical trials. The stories below reflect that spread, from a presenter's personal account to a scientific study on side effects.

Alison Hammond's comments stood out because she did not soften them for a UK audience still debating whether talking openly about Ozempic is appropriate. She lost 11 stone and made clear she sees no reason to downplay the role the drug played in that change. Her bluntness cuts against a pattern where celebrities credit diet and exercise alone, even when GLP-1 drugs are part of the picture. For readers on these medications, her willingness to say so plainly may feel like a relief, since it treats the drug as one tool among several rather than a secret.

Eli Lilly's potential stock split kept investors busy this week, with many looking back at how the company's shares behaved after past splits to guess what might happen this time. A stock split does not change the value of the company, but it does lower the price per share, which can make the stock more accessible to smaller investors and sometimes shifts trading patterns. History does not guarantee a repeat performance, but it gives investors a rough guide for what to expect. For readers who hold Lilly stock or are simply watching the company's fortunes, the split talk is a reminder that the business behind these drugs is also being read by markets, not only by doctors and patients.

Not every story this week was about progress. One writer described how getting significantly thinner left her flatter emotionally, not lighter, saying it dulled her pleasure and took away her usual optimism. Her account complicates the idea that reaching a lower weight automatically brings relief or happiness. It suggests some people experience unwanted effects in mood and outlook, not only on a scale. That kind of honesty, alongside Alison Hammond's, points to a willingness this week to talk about these drugs in more complicated terms than usual.

A new study added a more clinical note to that complexity, finding that men taking GLP-1 weight loss drugs may face a higher risk of hair loss than those who are not. Researchers have already documented this side effect in some patients, but this study specifically flagged the risk for men, an angle that had gotten less attention. The exact mechanism is not fully settled, and the finding does not mean hair loss is guaranteed or permanent. Still, it gives men considering these drugs one more factor to raise with their doctor before starting treatment.

Taken together, this week's stories show that the conversation around GLP-1 drugs keeps expanding into new territory, from financial markets to emotional side effects. If you are on one of these medications, pay attention to both what changes on the outside and what changes in how you feel day to day. Conversations like Alison Hammond's and the new hair loss data are useful reminders that these drugs come with a full range of effects, not just the ones tracked on a scale. If something feels off, whether that is your mood or something physical like hair loss, it is worth raising with your doctor.

Key details

• This week's roundup covers GLP-1 news from Novo Nordisk, Eli Lilly, Bupa, and UKHSA.

• UK presenter Alison Hammond spoke candidly about Ozempic after losing 11 stone.

• Eli Lilly's potential stock split has investors eyeing what history suggests could happen.

• One writer described how extreme thinness dulled her pleasure and usual optimism.

• A new study found that men taking GLP-1 weight loss drugs may face higher hair loss risk.

Read this on GLP-1 Nation: https://glp1nation.com/edition/39

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

Aspen Pharmacare's guidance points to a market that is still expanding quickly. The company expects Mounjaro sales across Africa to exceed $124 million (2 billion rand) in its current financial year, driven mainly by strong demand in South Africa. Aspen also has plans to launch the drug in Nigeria and Kenya, which would extend Eli Lilly's reach further across the continent. For Lilly, this expansion adds another growth market outside the more saturated US and European demand that has defined the GLP-1 story so far.

That kind of demand is not confined to adults. Reporting this week shows GLP-1 use among children under 12 in the United States has risen sharply, even though the FDA has not approved these drugs for that age group. Parents and doctors appear to be turning to off-label prescribing as interest in GLP-1 treatment spreads beyond its original approved uses. The trend raises questions about oversight and long-term safety data for a population that has not been studied in the same way adults have.

Eli Lilly's own investors got a more straightforward piece of news this week. Coverage described encouraging developments for the stock's outlook, adding to a run of good news for the company as its GLP-1 portfolio, including Mounjaro, continues to find new markets like the African launches Aspen is counting on.

Not every company in the GLP-1 market is getting the same reception from Wall Street. Citi reiterated its Sell rating on Novo Nordisk this week, pointing to signs that GLP-1 prescription growth is cooling. That call stands in contrast to the expansion Lilly is seeing through partners like Aspen, and it suggests the market may be starting to draw sharper lines between winners and laggards as the GLP-1 category matures.

Alongside the business news, a new study offers a reason for patients to pay attention beyond weight loss or diabetes control. Researchers report that GLP-1 drugs could help people live longer, adding to a growing body of research on the broader health effects of these medications. The findings are preliminary, but they add another dimension to why demand for these drugs keeps climbing in markets old and new.

The through-line here is that GLP-1 treatment keeps expanding into new markets and new age groups faster than the regulatory and investment picture can fully catch up. If you or someone in your family is using one of these drugs, or considering it, that gap is worth raising directly with a doctor rather than assuming approval or years of data automatically cover your situation. And if you are watching this as an investor, the split between Lilly's momentum and Novo Nordisk's slowing growth is a reminder that the category is no longer treated as a single story.

Key details

• Aspen Pharmacare projects Mounjaro sales across Africa will top $124 million this year.

• GLP-1 drug use among US children under 12 is rising sharply, despite lacking FDA approval.

• Eli Lilly investors received encouraging news this week about the stock's outlook.

• Citi kept its Sell rating on Novo Nordisk as GLP-1 prescription growth signals cooling.

• A new study suggests GLP-1 drugs could help people live longer, researchers report.

Read this on GLP-1 Nation: https://glp1nation.com/edition/38

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

The study, which has not yet been detailed beyond its headline finding, links weight loss injections to a reduction in severe snoring, a condition often tied to obesity and disrupted sleep. Researchers who track this drug class have already documented effects on blood pressure and cardiovascular risk, and this newest result suggests the benefits extend into areas patients may not expect when they start treatment for weight loss alone. Snoring itself is rarely dangerous, but severe cases are frequently a marker of obstructive sleep apnea, a condition linked to daytime fatigue and long-term heart strain. If further research confirms this connection holds across larger groups of patients, it would give doctors another reason to discuss these medications with patients whose weight is affecting their sleep, not just their metabolic health.

Novo Nordisk widened its footprint today by launching Wegovy in Germany, one of Europe's largest pharmaceutical markets and a country with a sizable population that could benefit from anti-obesity treatment. The German debut opens what analysts are describing as a new front for the company, extending its reach beyond markets where Wegovy already has an established presence. Novo Nordisk has faced growing competition from Eli Lilly's Zepbound in the U.S., so building volume in Europe gives the company a way to diversify its revenue rather than lean on a single region. For patients in Germany, the launch means broader access to a drug that has so far reached a comparatively small share of the market there.

As Novo Nordisk pushes to expand access to its existing drug, researchers working on the next generation of treatments say they have found early evidence of a weight loss approach that does not depend on eating less. Current GLP-1 drugs work in part by suppressing appetite, which helps patients eat smaller portions but can also bring side effects like nausea and, for some, a loss of muscle mass alongside fat. A treatment that produces weight loss without requiring reduced food intake would represent a different mechanism entirely, and could appeal to patients who struggle with the appetite suppression itself or who want an option that does not change their relationship with food. The study is still in its early stages, so more research is needed to determine whether this approach delivers weight loss on the same scale as existing GLP-1 drugs.

That search for an alternative mechanism appears to be advancing on another front. Scientists have developed a compound that cuts fat without curbing appetite, and unlike many existing weight loss drugs, it preserves muscle mass during the process. Muscle loss has been a persistent concern with GLP-1 medications, since patients can lose lean tissue along with fat, which may affect strength and metabolism over time. A compound that targets fat directly while sparing muscle and leaving appetite unchanged would address two of the more commonly reported drawbacks of current treatments, though it remains to be seen how far along this compound is in development or when it might reach patients.

The ripple effects of widening GLP-1 use are reaching into adjacent businesses as well. TD Securities said today that Establishment Labs, a breast implant maker, may be positioned to benefit as GLP-1 use continues to rise, since the firm is set to expand its breast implant business in the U.S. The connection reflects a pattern analysts have noted: as patients lose significant weight, some seek cosmetic procedures to address changes in body shape that weight loss can bring. For anyone watching the GLP-1 drug class from an investment angle, this kind of secondary effect is a reminder that the financial impact of these medications extends well past the companies that manufacture them.

The common thread across today's developments is that the effects of GLP-1 drugs keep extending past their original purpose, from sleep quality to international markets to companies that make cosmetic products. Patients should raise any new symptom or benefit, such as changes in snoring, with their own doctor rather than draw broad conclusions from a single early study. Anyone following this drug class from a financial standpoint might do well to track two things: how quickly newer compounds without appetite suppression move through development, and how established drugmakers like Novo Nordisk perform as they enter new countries. Both will shape how this drug class evolves over the coming years.

Key details

• Weight loss injections may help reduce severe snoring, according to a new study.

• Novo Nordisk has launched Wegovy in Germany, opening a new market for the drug.

• Researchers have found a weight loss treatment that doesn't require eating less.

• Scientists created a compound that cuts fat without curbing appetite and keeps muscle.

• GLP-1 growth may lift Establishment Labs, a breast implant maker, per TD Securities.

Read this on GLP-1 Nation: https://glp1nation.com/edition/37

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

The sell-off in Novo Nordisk shares today followed a downgrade from a major bank, and it reflects a broader unease about whether GLP-1 sales can keep growing at the pace investors have grown used to. Novo has built its valuation on the assumption that demand for drugs like Wegovy will keep expanding, so any sign of deceleration tends to hit the stock hard. Today's move suggests that some investors are recalibrating those growth expectations rather than dismissing them outright. That reassessment does not change what is happening to patients who are already taking these drugs, but it does hint at how closely Wall Street is watching prescription trends.

One of those patient stories, reported today, involved a woman with a documented history of anorexia who was prescribed a weight-loss injection despite that history. The case raises a real question about how carefully prescribers are screening for eating disorder history before recommending an appetite-suppressing drug. GLP-1 medications work by reducing hunger and food intake, which is the intended effect for someone managing obesity but can be a serious risk for someone recovering from or vulnerable to disordered eating. If you or someone you know has a history of anorexia or another eating disorder, I would suggest raising that history directly with a prescriber before starting a GLP-1 medication, rather than assuming it will come up on its own.

A related gap exists in Medicare's own discount program for these drugs. The program was designed to make GLP-1 medications more affordable, but reporting today found that some sick patients don't actually qualify for the discount because of how the eligibility rules are written. That leaves a group of patients who need the drug for a covered condition but fall outside the specific criteria Medicare set, so they end up paying more than the discount was supposed to guarantee. For anyone relying on Medicare to cover or discount a GLP-1 prescription, I would suggest confirming eligibility directly with Medicare or a pharmacist before assuming the discount will apply.

Longer-term data suggests the calculus around starting a GLP-1 drug may look different depending on age. A new study reported today found that beginning GLP-1 treatment at 62 could add roughly a decade to life expectancy. That is a meaningful figure, and it suggests the benefit of starting treatment may be tied not just to weight loss itself but to how early in a person's health trajectory the drug is introduced. It is a reminder that decisions about starting or delaying a GLP-1 prescription are worth discussing with a doctor in the context of age and overall health, not just current weight.

That kind of long-term promise is part of what makes today's Citi downgrade notable by comparison. Citi's own explanation for cutting its rating on Novo Nordisk pointed specifically to slowing growth in GLP-1 demand, not to any single safety or eligibility issue reported elsewhere today. In other words, the bank's concern is about the pace of new prescriptions and market expansion, separate from the patient-level questions raised by the anorexia case or the Medicare discount gap. Investors reading today's downgrade should keep in mind that a slowdown in demand growth does not necessarily mean demand is shrinking, only that it may be leveling off from an unusually steep climb.

Today's news splits into two clear tracks. One track is financial: Citi's downgrade and Novo Nordisk's stock decline reflect how sensitive the GLP-1 market is to any sign of slowing growth. The other track is personal: the anorexia prescribing case and the Medicare discount gap both point to how much access to these drugs still depends on individual circumstances, not just broad approval. If you are considering a GLP-1 prescription, take the time to discuss your full health history with your prescriber and confirm your specific coverage details with Medicare or your insurer, rather than assuming general rules will apply to your situation.

Key details

• Novo Nordisk's stock fell after a bank downgrade tied to concerns about slowing growth.

• A woman with anorexia history was prescribed a weight-loss injection anyway.

• The Medicare discount for GLP-1 drugs doesn't cover some sick patients who don't qualify.

• Starting GLP-1 jabs at 62 could add a decade to life expectancy, a study suggests.

• Citi cited slowing GLP-1 demand growth as the reason for its Novo Nordisk downgrade.

Read this on GLP-1 Nation: https://glp1nation.com/edition/36

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

Novo Nordisk, the company that built its recent success on Ozempic, is now looking past its blockbuster injectable to secure its next chapter of growth. According to a New York Times report, oral versions of its GLP-1 drugs may be the company's answer as competition intensifies and current products mature. Moving from injections to pills could make treatment easier for patients who prefer not to use needles, and it could open the drug to people who have avoided treatment for that reason. This shift in strategy comes as the company faces increasing competitive pressure, both from other companies and from new formulations of its own drugs.

Access is also improving on the cost side for a large group of patients. A new Medicare program now allows hundreds of thousands of patients to pay just $50 a month for GLP-1 drugs, a sharp drop from out-of-pocket costs that could previously exceed $1,000 a month. This change removes one of the biggest barriers that has kept eligible patients from starting or continuing treatment. For many older adults managing diabetes or related conditions, this pricing shift could mean the difference between consistent treatment and going without it.

As more patients gain access to these drugs, the FDA is also expanding what they are approved to treat. On August 28, the agency approved Mounjaro (tirzepatide) for reducing cardiovascular risk in adults with type 2 diabetes, adding to its existing approvals for blood sugar control and weight management. This approval gives doctors another reason to consider Mounjaro for patients who face heart related complications alongside diabetes. It also reflects a broader trend in the GLP-1 category, where drugs originally developed for one purpose are proving useful for several related health outcomes.

That broader trend is playing out directly in Novo Nordisk's stock performance. The company's shares steadied after the launch of a Wegovy pill in Germany, a milestone that highlighted just how much the obesity treatment market continues to grow. Investors have been watching closely for signs that Novo Nordisk can keep pace with competitors, and this launch offered some reassurance. The stock reaction shows how closely tied Novo Nordisk's financial outlook is to its ability to expand into new formulations and new markets.

Not all of today's attention on these drugs is about medicine or markets. Rep. Andy Ogles publicly blamed Ozempic for country singer Jelly Roll's recent comments about former President Trump, a claim that has drawn attention mostly for how it reflects public perception of the drug rather than any medical basis. The comment illustrates how Ozempic has become a shorthand reference in political and cultural commentary, often disconnected from its actual clinical use. It also shows how a drug developed for diabetes and weight management has become a recognizable name well beyond the health care conversation.

Across these stories, GLP-1 drugs are expanding in nearly every direction at once: in the forms they take, the costs patients pay, the conditions they treat, and the public conversations they generate. If you are a patient, it may be worth checking whether new pricing programs or expanded approvals apply to your treatment plan. For readers simply following the news, remember that this category is moving quickly, so it helps to separate real clinical developments from commentary that treats these drugs as a cultural symbol rather than a medical treatment.

Key details

• Novo Nordisk, the company behind Ozempic, may turn to pill versions for future growth.

• Hundreds of thousands of Medicare patients now pay just $50 for GLP-1 drugs monthly.

• The FDA approved Mounjaro to cut cardiovascular risk for adults with type 2 diabetes.

• Wegovy's pill launch in Germany helped steady Novo Nordisk's stock amid obesity growth.

• Rep. Andy Ogles blamed Ozempic for country singer Jelly Roll's comments about Trump.

Read this on GLP-1 Nation: https://glp1nation.com/edition/35

Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.

The new Medicare pilot is designed to streamline access to GLP-1 drugs and bring the price down to $50 a month for some enrollees. That sounds promising, but the program's rules mean people with the most serious illnesses may not be covered under this discount. If you or a family member rely on Medicare for these medications, I would suggest checking the specific eligibility terms before assuming the lower price applies. Coverage details can vary based on diagnosis and plan, so a call to your provider or Medicare directly is a reasonable next step.

Separately, the FDA has expanded the approved uses for Mounjaro, Eli Lilly's popular diabetes drug. This means doctors now have more flexibility in prescribing it for conditions beyond its original approval. For patients already on Mounjaro, this broader approval could open the door to insurance coverage for uses that were previously off label. Anyone curious about whether this change affects their own treatment should raise it with their prescriber at their next visit.

Some GLP-1 users are reporting that food has become less appealing to them, a known effect of how these drugs work on appetite and reward signals in the brain. In place of that interest in food, some people say they have developed a new, costly focus for their attention and spending. This shift is a reminder that GLP-1 medications can change more than weight, and patients may want to watch for changes in habits or spending that surprise them. If you notice this kind of shift in yourself or someone you care about, it may be worth mentioning to a doctor.

In Brazil, a black market for weight-loss drugs has grown substantially, and smugglers are profiting from the demand. Routes like the Friendship Bridge between Brazil and Paraguay, once used mainly for cigarettes and electronics, are now serving as passageways for illicit weight-loss medications. This growth in illegal supply chains raises safety concerns, since drugs obtained this way are not subject to the same quality controls as those sold through legitimate pharmacies. Readers should be cautious about sourcing any GLP-1 medication outside of a licensed provider, regardless of where they live.

Leslie Mann has said that her husband, director Judd Apatow, has gained weight since starting Ozempic. This detail stands out because it runs counter to the drug's most publicized effect, and it is a useful reminder that individual responses to GLP-1 medications can vary. Weight outcomes depend on a range of factors, including dosage, diet, and how a person's body responds over time. Anyone tracking their own progress on these medications should keep in mind that results are not identical from person to person.

Taken together, these stories show how unevenly the GLP-1 story is unfolding depending on where you sit, whether that is a Medicare enrollee checking eligibility, a patient watching for new side effects, or someone weighing where to safely obtain a prescription. The details matter more than the headlines here, so if any of these updates apply to your situation, take the time to confirm the specifics with your doctor, pharmacist, or insurance provider before making a decision.

Key details

• Medicare's new pilot offers $50-a-month GLP-1s to some seniors, though not all qualify.

• The FDA has broadened approved uses for Eli Lilly's Mounjaro, a popular diabetes drug.

• Food is becoming less appealing to some GLP-1 users, who now chase a costly new obsession.

• Smugglers are profiting as Brazil's black market for weight-loss drugs keeps growing.

• Leslie Mann said her husband Judd Apatow has gained weight since taking Ozempic.

Read this on GLP-1 Nation: https://glp1nation.com/edition/34